NCT00121095View on ClinicalTrials.gov

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

June 30, 2008

Conditions
Prostatic Neoplasms
Interventions
DRUG

Samarium Sm-153 lexidronam + Docetaxel

1 mCi/kg Sm153 + 75 mg/m2 docetaxel

Trial Locations (1)

10021

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Cytogen Corporation

INDUSTRY